Sanofi-Aventis drops two late-stage products
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis is to discontinue the development of two late-stage products, its chronic insomnia drug Ciltyri (eplivanserin) and the anti-thrombotic idrabiotaparinux.